We are a Swiss law firm, dedicated to providing legal solutions to business, tax and regulatory matters.
Dedicated to our clients' success
Services
Intellectual Property
Life Sciences, Pharma, Biotech
Litigation and Arbitration
Meet our team
Our knowledge, expertise & publications
View all
Events
Deals & Cases
Careers
25 July 2022
Mosanna Therapeutics AG, a Basel-based biotechnology company developing the advanced small molecule MOS118 (formerly know as AVE0118) for the treatment of metabolic obstructive sleep apnea, closes a Seed Financing Round led by Forty51 Ventures. The proceeds will be used for formulation and manufacturing optimization of MOS118 and for regulatory activities in preparation of the first Phase 1b clinical trial. VISCHER advises Mosanna Therapeutics AG since its incorporation on all Swiss legal matters. The VISCHER team includes Matthias Staehelin (Partner) and Timothy Woodtli (Associate), both Corporate/M&A.
Categories: Corporate and commercial, Life Sciences, Pharma, Biotech, Private Equity & Venture Capital, Startup Desk
Attorney at Law and Civil Law Notary (BS/BL)
Attorney at Law
Swiss dental startup Odne (former Lumendo) has raised USD 5.5m to fund the upcoming US market launch...
Artiria Medical SA, a Swiss neurovascular MedTech company developing next-generation...
GlycoEra AG in Wädenswil, has increased its Series A Financing Round with a substantial additional...